Effects of BCR-ABL inhibitors on anti-tumor immunity

M Krusch, HR Salih - Current medicinal chemistry, 2011 - ingentaconnect.com
In chronic myeloid leukemia (CML), BCR-ABL-mediated oncogenic signaling can be
successfully targeted with the BCRABL-inhibitors imatinib, nilotinib, and dasatinib leading to …
被引用次数：24 相关文章

Effects of BCR-ABL inhibitors on anti-tumor immunity.

M Krusch, HR Salih - Current Medicinal Chemistry, 2011 - europepmc.org
In chronic myeloid leukemia (CML), BCR-ABL-mediated oncogenic signaling can be
successfully targeted with the BCRABL-inhibitors imatinib, nilotinib, and dasatinib leading to …

[引用][C] Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity

M Krusch, HR Salih - Current Medicinal Chemistry, 2011 - cir.nii.ac.jp

Effects of BCR-ABL inhibitors on anti-tumor immunity

M Krusch, HR Salih - Current medicinal chemistry, 2011 - pubmed.ncbi.nlm.nih.gov
In chronic myeloid leukemia (CML), BCR-ABL-mediated oncogenic signaling can be
successfully targeted with the BCRABL-inhibitors imatinib, nilotinib, and dasatinib leading to …

[引用][C] Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity: Targeting the Microenvironment in Hematological Malignancies: How to Condition both Stromal and …

M KRUSCH, HR SALIH - Current medicinal chemistry, 2011 - pascal-francis.inist.fr
Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity : Targeting the Microenvironment in
Hematological Malignancies: How to Condition both Stromal and Effector Cells to …

[引用][C] Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity

M KRUSCH, HR SALIH - Current medicinal chemistry, 2011 - Bentham